Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3.

Autor: Asensio M; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain., Briz O; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain., Herraez E; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain., Perez-Silva L; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain., Espinosa-Escudero R; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain., Bueno-Sacristan D; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Service of Pathology, University Hospital of Salamanca, Salamanca, Spain., Peleteiro-Vigil A; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain., Hammer H; Signatope GmbH, Reutlingen, Germany., Pötz O; Signatope GmbH, Reutlingen, Germany; Natural and Medical Sciences Institute at the University of Tubingen (NMI), Reutlingen, Germany., Kadioglu O; Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany., Banales JM; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain; Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), Ikerbasque, San Sebastian, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain., Martinez-Chantar ML; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain; Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CICbioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain., Avila MA; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain; Hepatology Laboratory, Solid Tumors Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain., Macias RIR; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain., Efferth T; Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany., Marin JJG; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain. Electronic address: jjgmarin@usal.es., Lozano E; Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain.

Publikováno v: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Nov; Vol. 180, pp. 117533. Date of Electronic Publication: 2024 Oct 13.

Dicloxacillin is an inducer of intestinal P-glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users.

Autor: Iversen DB; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark., Dunvald AD; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark., Ernst MT; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark., Abtahi S; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands., Souverein P; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands., Klungel O; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands., Jeppesen GB; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark., Nielsen F; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark., Brøsen K; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark., Hammer HS; Signatope GmbH, Reutlingen, Germany., Pötz O; Signatope GmbH, Reutlingen, Germany.; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Damkier P; Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Järvinen E; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark., Pottegård A; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark., Stage TB; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.; Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Aug 19. Date of Electronic Publication: 2024 Aug 19.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide.

Autor: Ortiz-Rivero S; Experimental Hepatology and Drug Targeting (HEVEPHARM), Spain; Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, Madrid, Spain., Peleteiro-Vigil A; Experimental Hepatology and Drug Targeting (HEVEPHARM), Spain; Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain., Abete L; SIGNATOPE GmbH, Reutlingen, Germany., Lozano E; Experimental Hepatology and Drug Targeting (HEVEPHARM), Spain; Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, Madrid, Spain., Hammer HS; SIGNATOPE GmbH, Reutlingen, Germany., Giacomo SD; Department of Physiology and Pharmacology 'V. Erspamer', Sapienza University of Rome, Rome, Italy; Department of Food Safety, Nutrition and Veterinary Public Health, National Institute of Health, Rome, Italy., Abad M; Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain., Boix L; BCLC Group, IDIBAPS, Barcelona, Spain., Forner A; Liver Oncology Unit, Liver Unit, ICMDM, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, Madrid, Spain., Reig M; Liver Oncology Unit, Liver Unit, ICMDM, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, Madrid, Spain., Macias RIR; Experimental Hepatology and Drug Targeting (HEVEPHARM), Spain; Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, Madrid, Spain., Pötz O; SIGNATOPE GmbH, Reutlingen, Germany; NMI Natural and Medical Sciences Institute, University of Tuebinegn, Reutlingen, Germany., Marin JJG; Experimental Hepatology and Drug Targeting (HEVEPHARM), Spain; Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, Madrid, Spain. Electronic address: jjgmarin@usal.es., Briz O; Experimental Hepatology and Drug Targeting (HEVEPHARM), Spain; Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, Madrid, Spain.

Publikováno v: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Jan; Vol. 170, pp. 116038. Date of Electronic Publication: 2023 Dec 22.